| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Immunology, Imperial College, London, UK
2 Department of Genito-Urinary Medicine and Communicable Diseases, Imperial College, London, UK
3 GlaxoSmithKline Biologicals, Belgium
4 Department of Immunology, Graduate School and Faculty of Medicine, University of the Ryukyus, Japan
Correspondence
Becca Asquith
b.asquith{at}imperial.ac.uk
Charles R. M. Bangham
c.bangham{at}imperial.ac.uk
The CD8+ lymphocyte response is a main component of host immunity, yet it is difficult to quantify its contribution to the control of persistent viruses. Consequently, it remains controversial as to whether CD8+ cells have a biologically significant impact on viral burden and disease progression in infections such as human immunodeficiency virus-1 and human T-lymphotropic virus type I (HTLV-I). Experiments to ascertain the impact of CD8+ cells on viral burden based on CD8+ cell frequency or specificity alone give inconsistent results. Here, an alternative approach was developed that directly quantifies the impact of CD8+ lymphocytes on HTLV-I proviral burden by measuring the rate at which HTLV-I-infected CD4+ cells were cleared by autologous CD8+ cells ex vivo. It was demonstrated that CD8+ cells reduced the lifespan of infected CD4+ cells to 1 day, considerably shorter than the 30 day lifespan of uninfected cells in vivo. Furthermore, it was shown that HTLV-I-infected individuals vary considerably in the rate at which their CD8+ cells clear infected cells, and that this was a significant predictor of their HTLV-I proviral load. Forty to 50 % of between-individual variation in HTLV-I proviral load was explained by variation in the rate at which CD8+ cells cleared infected cells. This novel approach demonstrates that CD8+ cells are a major determinant of HTLV-I proviral load. This assay is applicable to quantifying the CD8+ cell response to other viruses and malignancies and may be of particular importance in assessing vaccines.
Supplementary material is available in JGV Online.
These authors contributed equally to this work.
This article has been cited by other articles:
|
|
 |
|
  F. Toulza, A. Heaps, Y. Tanaka, G. P. Taylor, and C. R. M. Bangham High frequency of CD4+FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response Blood, May 15, 2008; 111(10): 5047 - 5053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Asquith, Y. Zhang, A. J. Mosley, C. M. de Lara, D. L. Wallace, A. Worth, L. Kaftantzi, K. Meekings, G. E. Griffin, Y. Tanaka, et al. In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection PNAS, May 8, 2007; 104(19): 8035 - 8040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. De Boer Understanding the Failure of CD8+ T-Cell Vaccination against Simian/Human Immunodeficiency Virus J. Virol., March 15, 2007; 81(6): 2838 - 2848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Mosley, K. N. Meekings, C. McCarthy, D. Shepherd, V. Cerundolo, R. Mazitschek, Y. Tanaka, G. P. Taylor, and C. R. Bangham Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infection Blood, December 1, 2006; 108(12): 3801 - 3807. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
